FormalPara Key Summary Points

Carfentanil, protonitazene, and isotonitazene are three new synthetic opioids that negatively contribute to the opioid pandemic. The potency and effectiveness of these synthetic opioids significantly enhance the risk of overdose and have increased mortality

These readily available, inexpensive fentanyl analogs have permeated the drug market. According to the case studies, a pattern of drug users with substance use disorders dying from overdoses after ingesting narcotics laced with carfentanil has arisen

The OUD treatment recommendations that are now in place present additional difficulties. The dose of naloxone advised does not seem to be sufficient to reverse the effects of the synthetic opioids

To deal with these more potent synthetic opioids, the recommended naloxone dosage and course of therapy must be modified. To find effective alternative reversal treatments for overdoses and alternative pain-relieving formulas/medications, advanced and accelerated pharmaceutical research is essential

As time goes on, the opioid issue will require cooperation from the medical community, policymakers, and law enforcement. To effectively treat OUD, lessen addiction, and stop further substance use, a variety of entities, agencies, and procedures can all be put into place simultaneously, from education about OUD treatment and proper guidelines to pharmacological developments

Additionally, educating the public on the risks posed by the new synthetic opioids, particularly for those at risk, and offering assistance to those in need may help lower the incidence of fatal overdoses

Introduction

An opioid crisis in the US began in the 1990s when prescription opioid use accelerated, followed by a second wave in 2010 related to heroin use [1]. In 2013, the popularity of illicit synthetic opioid use, such as fentanyl, led to the third wave of the crisis, causing a marked increase in fatal overdoses [1]. Synthetic opioid use is nearly twice as likely to lead to an overdose death compared with prescription opioids or heroin [1, 2]. The low production cost and high potency of fentanyl make it an attractive substance to mix with heroin and other illicit drugs [3]. Since its introduction, fentanyl and its analogs have infiltrated the US heroin supply. They are found in pills that look like commonly known opioids or benzodiazepines and are known as “pressed pills” [4].

Fentanyl and its analogs cause severe central nervous system (CNS) and respiratory depression, which may lead to death, especially in an unsuspecting, opioid-naive person [4]. Fentanyl analogs are emerging at an alarming rate, and their detection can be difficult since they often have novel chemical structures [4]. Another challenge is found in internet distribution, which makes these drugs more attainable and can cause confusion between pharmaceutically and illicitly manufactured opioids [5]. To combat these growing challenges, clinicians should recognize the hallmark signs of opioid toxicity, such as respiratory distress, altered mental status, and miosis [4]. Concerning emergency overdose treatment, a larger dose of naloxone is required to reverse the effects of high-potency opioids compared with heroin, up to the point that repeated doses or a naloxone may be needed to control respiratory depression [4]. This is related to the fact that fentanyl is very potent, allowing it to outcompete naloxone for the mu opioid receptor (MOR). Further, because it is very lipophilic, it will stay in the body longer than other opioids. This narrative review, therefore, aims to highlight the clinical challenges presented by these new synthetic opioids.

Compliance with Ethical Guidelines

This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors. This was a narrative review. The sources for this review are as follows: searching on PubMed, Google Scholar, Medline, and ScienceDirect from 1990 to 2022 using combinations of the keywords: synthetic opioids, fentanyl, carfentanil, protonitazene, isotonitazene, overdose. We attempted to include as many primary sources as possible.

Dangers of Synthetic Opioids

Since the early 2010s, synthetic opioids have significantly contributed to overall opioid-related overdose mortalities. For reference, of the 68,630 opioid-related deaths recorded in 2020, 56,516 involved synthetic opioids (primarily fentanyl and its analogs) [6, 7]. This rise in synthetic-opioid related use in recent years has been accompanied by a corresponding, decrease in the use of other illicit opioids such as heroin [8]. Some potential reasons why synthetic opioid use has become so ubiquitous have been postulated to include lower production costs, stronger or longer lasting highs, and increasingly efficient synthesis by manufacturers [8, 9]. As noted by the US Drug Enforcement Agency, a relatively common factor in synthetic opioid overdoses is their utilization as cheap adulterants in preparations of other illicit drugs [10]. This is not to say that there are not users who intentionally seek out synthetic opioids. Still, the role of synthetic opioids as additives unknown to the user is nevertheless thought to play a significant role. Fentanyl and other synthetic opioids have been detected as components in mixtures of cocaine, methamphetamine, heroin, and counterfeit pills [11]. The increased danger of overdose from synthetic opioids versus substances such as heroin is simply related to their greatly increased potency and efficacy, as well as increased availability in the drug supply [12]. What may be a “typical” dose of an opioid like heroin is certainly lethal without rapid intervention when a synthetic opioid like fentanyl or carfentanil is substituted in its place. Furthermore, heroin overdose can take 20–30 min before it leads to a fatality. Fentanyl, on the other hand, can precipitate a profoundly dangerous and life threatening respiratory arrest within 2–5 min [12].

Presentation

The signs and symptoms of overdose from synthetic opioids are essentially the same as those seen from overdose secondary to natural and semisynthetic opioids. Through various pharmacological mechanisms, synthetic opioids potently act on the CNS to produce various effects, ranging from euphoria and analgesia to respiratory depression, coma, and death [12]. Respiratory arrest followed by death is the most serious outcome of an overdose. However, even nonfatal overdoses can produce variably debilitating results, with life-altering effects such as permanent parkinsonism or psychosis secondary to hypoxic brain injury [12]. The treatment of opioid overdose revolves chiefly around restoring a patient’s ability to spontaneously breath. As is standard in treating opioid overdoses in general, the MOR antagonist naloxone is the first-line medication for reversal in the case of synthetic opioid overdose. Given the increased potency of synthetic opioids, it has been hypothesized that increased dosages of naloxone are necessary to reverse their effects [11, 13]. Additionally, given the wide therapeutic window of naloxone, and with the increasing prevalence of these substances in circulation, suggestions have been made to simply increase the standard doses of naloxone administered by the first responders who initially arrive on scene to an opioid overdose [12].

New Synthetic Opioids Overview

Carfentanil

Carfentanil is an extremely potent fentanyl-derivative initially circulated in the mid-1980s as a general anesthetic for large animals such as elephants. Currently, carfentanil still sees medical and scientific use as a radiotracer for positron emission tomography imaging, related to its high affinity for MORs in brain tissue [14]. Outside of its legitimate clinical uses, carfentanil is commonly known by street-names such as “drop dead” and “elephant tranquilizer”. It has been commonly found as an additive in other illicit drugs such as heroin and cocaine, meaning many unwitting users may be completely unaware of its presence [15]. As carfentanil is not regularly tested for in most routine drug screening panels, investigators are still unsure of the extent to which it contributes to yearly opioid overdose deaths. It is suspected, however, that it plays a significant role. For instance, one recent report demonstrated that a large spike and fall of opioid-related overdose deaths between 2016 and 2017 correlated with the amounts of carfentanil seized by the authorities [16].

As a fentanyl derivative, carfentanil produces effects similar to other opioids, including analgesia, euphoria, bradycardia, respiratory depression, hypotension, loss of consciousness, and death. What sets carfentanil apart from most other opioids is its extremely high potency. For instance, it is over 1000 times more potent than morphine at the MOR, and its affinity for the MOR is 50 times greater than fentanyl [17]. Given the implication of MOR in respiratory depression, the high potency of carfentanil means that even very small doses can produce extremely rapid detrimental effects. Carfentanil may be found in pill, powder, and liquid forms [15]. As is common practice in reversing overdose due to other opioids, the accepted method for treating carfentanil overdose relies on the pure MOR antagonist naloxone. Recent clinical studies have suggested that higher doses of naloxone may be necessary to reverse carfentanil’s effects. However, further analysis is needed to confirm this with certainty [17, 18].

Protonitazene

Protonitazene belongs to a novel class of synthetic opioids that was initially manufactured in the 1950s as a potential alternative opioid for medical use [19]. Related to observed adverse effects in early clinical trials, its study for medical use was discontinued. For the majority of the time since its original manufacture in the mid-twentieth century, protonitazene remained rather obscure. This ceased to be the case between 2019 and 2021, when protonitazene was found in forensic analysis in cases seen in the USA, Canada, Europe, and Australia [19, 20]. As its appearance as an illicit drug remains relatively recent, protonitazene remains unregulated in the European Union at the time of this present writing. The USA has now classified protonitazene as a Schedule I substance [19]. Manufacture has been linked to various companies in China that offer shipping to other countries via online sales.

As a member of the novel opioid subclass of benzimidazoles, protonitazene behaves as a strong MOR agonist with a high potentiality for addiction [21]. Analyses of protonitazene have demonstrated that at the MOR, it possesses an efficacy of approximately 1.07–1.29 times greater than that of fentanyl, and its potency is much greater than morphine [19]. Other opioids share common effects: analgesia, euphoria, respiratory depression, coma, and potentially death [21, 22]. Protonitazene appears to be primarily manufactured for illicit use in tablet and powder forms, though it has also been found in liquid form [19, 22]. As with other synthetic opioids, there is serious potential for protonitazene to be used as an additive in other illicit drugs, leading to unwitting overdose by the user [22]. As a recent Australian study noted, the effects of synthetic opioids such as protonitazene can be highly unpredictable, leading to a high risk of accidental overdose in even experienced users [20]. In the case of overdose, naloxone has been shown to successfully reverse protonitazene in a clinical setting [20].

Isotonitazene

Like protonitazene, isotonitazene also belongs to the novel benzimidazole class of opioids. It was also initially synthesized in the 1950s [23]. This drug never saw any medical use and remained in relative obscurity until being identified by authorities in Midwestern USA in 2019 [24]. Reports of isotonitazene use in the USA are still fairly uncommon at present. However, in mid-2020, the USA classified isotonitazene as a Schedule I substance [25]. Like protonitazene, the primary source of isotonitazene is China, where manufacturers synthesize the product and market it overseas [24].

As with the other substances in this study, many of the primary effects of isotonitazene are mediated through MOR agonism. Isotonitazene’s potency is comparable to fentanyl, which may be found in pill, powder, and liquid forms [25]. As expected, the effects of isotonitazene range from euphoria and analgesia to respiratory depression, coma, and death [23]. As with other synthetic opioids, much of the isotonitazene sold on the streets is not marketed as isotonitazene. The Drug Enforcement Agency (DEA) has reported that most of the isotonitazene that has been analyzed in the USA so far was utilized as a cheap filler for other illicit substances such as heroin, or sold as counterfeit versions of opioids such as hydromorphone [24]. At present, there is still limited data regarding how often isotonitazene is implicated in drug overdoses. Given the lack of data, there have yet to be any studies addressing the recommended dosage of naloxone needed to reverse isotonitazene overdose. It is suspected, however, that a higher dose than that usually employed for opioid overdose may be required [25]. Table 1 lists the synthetic opioids reviewed in this section and their strengths relative to both fentanyl and morphine.

Table 1 Synthetic opioids and their strengths relative to both fentanyl and morphine
Full size table

Treatment Challenges with Fentanyl and Other Synthetic Opioids

The rise of fentanyl and its analogs have brought many challenges to treating opioid use disorder (OUD) [26]. One of which is that fentanyl’s pharmacologic profile has a higher potential of addiction and overdose deaths compared with morphine and heroin [27]. Fentanyl is a full-efficacy MOR agonist that is 50 to several 100 times more potent than morphine, depending on the route of administration [27]. Fentanyl’s lipophilicity allows for rapid plasma distribution and the ability to cross the blood–brain barrier. This is one of the features responsible for fentanyl’s faster onset, shorter analgesic duration, and higher analgesic potency compared with morphine [28]. As stated earlier, along with the potency of fentanyl, it also contributes to why higher amounts of naloxone may be needed to reverse a fentanyl-related overdose.

Another challenge at hand is that the current OUD treatment guidelines were created for morphine and heroin, which have a much lower potency compared with the new synthetic opioids [29]. Fentanyl users are at a greater risk of precipitated withdrawal by buprenorphine when treatment is initiated [30, 31]. The withdrawal mechanism may be due to fentanyl’s lipophilicity, which causes prolonged and varied renal clearance, or due to MOR desensitization/availability [30]. Current methadone treatment protocols are conservative, and the dosing regimen does not reach a therapeutic dose quickly enough, causing a lack of perceived efficacy in patients [29]. Through ongoing research, it is pertinent that optimal treatment strategies and dosing for fentanyl-related OUD are created regarding buprenorphine, methadone, and naloxone [28]. The addition of short-acting opioids in treating patients with acute pain and withdrawal symptoms can be a helpful tool [26]. Unfortunately, many physicians fear exacerbating addiction or lack training to treat OUD with short-acting opioids [26]. In addition to research, policies and regulations need to be implemented and physician education on proper treatment of synthetic OUD so that patients fighting OUD can receive proper and adequate treatment moving forward [32].

Treatment challenges exist within the education and administration of pain management medications [26]. With fentanyl and fentanyl analogs being on the rise and the tenfold increase in mortality within the first 4 weeks after discontinuation of methadone treatment, follow-up and aftercare need adaptation and improvement [29]. Hospital protocols, clinician training in addiction, and legal restrictions have perpetuated ongoing challenges to successfully and effectively manage pain and limit addiction and overdose [26]. Challenges further exist with discharge planning and compliance with sufficient post-discharge and follow-up treatments [26]. Application and integration of ongoing research and evidence-based treatment, as well as protocols and the integration and collaboration of addiction consultants for inpatient clinicians may also overcome the preceding challenges [26]. With all this in mind, it is time to turn to clinical cases involving these synthetic opioids.

Clinical Cases

Clinical Considerations for Detection of New Synthetic Opioids

Selected Case Reports

The selected case reports below detail the unique challenges with detection, management, and clinical presentation of acute intoxication with various synthetic opioids. All blood analyses, toxicology screenings, autopsy reports, and certified cause of death were included wherever available. Additional history and laboratory testing of drug paraphernalia were included wherever applicable. Table 2 contains the pertinent history, toxicology findings, and cause of death from these selected cases, as well as additional cases of confirmed synthetic opioid intoxication.

Case 1: Acute carfentanil intoxication [33].

A 38-year-old male with a known history of heroin use was found deceased in his bathroom surrounded by drug paraphernalia. Analysis of the femoral blood showed carfentanil (221 ng/L) without evidence of any other drugs, although urine screening was positive for morphine, codeine, hydromorphone, and norfentanyl. Autopsy showed pulmonary congestion and cardiomegaly. Toxicology results and autopsy findings indicated carfentanil drug toxicity as the cause of death [33].

Case 2: Acute protonitazene intoxication [34].

A 41-year-old male with a known history of substance use was found deceased in his hotel room after illicit drug use with his girlfriend. They had received drugs from an unknown source that they believed to be cocaine. After consuming these illicit drugs, she left the hotel room to go to the vending machine, but upon returning to the hotel room she found him lying on the bed with his fists clenching his chest holding his cell phone. Investigators also found an unspecified pill on the side table next to the bed. Analysis of cardiac blood was positive for protonitazene (1400 ng/mL), etodesnitazene (1.8 ng/mL), cocaine (1500 ng/mL), benzoylecgonine (3100 ng/mL), cocaethylene (260 ng/mL), delta-8 tetrahydrocannabinol (THC)(9.0 ng/mL), delta-9 tetrahydrocannabinol (THCC) (6.8 ng/mL), doxepin (110 ng/mL), and ethanol (47 mg/dL). Autopsy findings were unavailable, but the cause of death was listed as mixed drug toxicity [34].

Case 3: Acute isotonitazene intoxication and withdrawal [35].

A man with a known history of smoking isotonitazene was found deceased in his home. He had voluntarily admitted himself for isotonitazene detoxification 2 months prior. During that hospitalization, he described how he had developed an addiction to the relaxant and euphoric effects of isotonitazene that quickly lead to a physical dependence requiring greater and greater doses to avoid withdrawal. He explained that his previous withdrawal symptoms often included sweating, nausea, jaw tension, and intense psychic stress. While detoxing in the hospital, he exhibited psychomotor agitation, insomnia, and episodes of cold sweats consistent with opioid withdrawal. The patient was discharged after only 7 days at his request following the cessation of withdrawal symptoms. Providers in the hospital conducted a psychoeducational interview and determined that his judgment was intact with the absence of cravings; therefore, he was allowed to leave [35].

Upon discovering his body 2 months later, investigators found a vaporization pipe and a white powdery substance later confirmed to be isotonitazene. Autopsy findings revealed gastric material in the upper and lower respiratory tract. Analysis of his hair confirmed isotonitazene use in the month between his discharge and subsequent death. Femoral blood analysis was positive for isotonitazene (0.59 ng/mL), lorazepam (12 ng/mL), THC (56 ng/mL), 11-hydroxy-THC (1.8 ng/mL), carboxy-THC (6.5 ng/mL), and cannabinol (CBN) (2.9 ng/mL). The higher concentrations of isotonitazene distributed throughout the body compared with the femoral blood and his significant history were highly suggestive of isotonitazene intoxication leading to his death [35].

Case 4: Positive central blood screening with confirmed synthetic opioids at the scene [33].

A 38-year-old male with a known history of alcoholism was found deceased on the floor of his friend’s bathroom. His family denies any history of illicit drug use, but drug paraphernalia including a syringe, spoon, and powdery substance was found at the scene. Analysis of the powdery substance identified a mixture of heroin, fentanyl, and carfentanil. No formal autopsy was conducted but given the presence of opioids and track marks on the decedent’s arms, further toxicology analysis was performed. Initial urine screening was positive for morphine, hydromorphone, fentanyl, and norfentanyl, but there was no evidence of carfentanil. Carfentanil (30.1 ng/L) was only identified after analysis of the subclavian blood [33].

Case 5: Negative peripheral blood screening despite a history suggestive of opioid use [36].

A 34-year-old male with a history of tobacco, alcohol, marijuana, and heroin use was found deceased in his van. Various drug paraphernalia including a syringe, spoon, and yellow baggy with a brown substance was found in the van. Analysis of the spoon identified caffeine, carfentanil, diphenhydramine, fentanyl, para-fluoroisobutyryl fentanyl, furanyl fentanyl, heroin, hydromorphone, mannitol, 6-monoacetylmorphine, morphine, noscapine, and quinine. Initial peripheral blood testing was negative, but given the presence of synthetic opioids identified on the drug paraphernalia additional cardiac blood screening was performed. Heart blood was positive for carfentanil (1.3 ng/mL), furanyl fentanyl (0.34 ng/mL), morphine (< 20 ng/mL), and hydromorphone (< 20 ng/mL). Additional urine screening was positive for morphine, hydromorphone, 6-monoacetylmorphine, and hydrocodone. Autopsy findings include mild hypertensive heart disease with left ventricular hypertrophy and mild hepatic steatosis. Given the history and positive cardiac blood toxicology, cause of death was listed as mixed drug intoxication [36].

Case 6: Targeted screening for low-dose synthetic opioid [36].

A 25-year-old male with a history of tobacco, alcohol, marijuana, spice, and prescription pain medication use was found face down on a mattress in a tent where he had been living with his mother. Before his death, he complained of “itching all over” and his sister described him as sounding “very intoxicated.” Initial peripheral blood screening was positive for benzoylecgonine (460 ng/mL). His urine screening was highly suggestive of carfentanil, but these results were inconclusive due to the relatively low dose. Given his symptoms of “itching all over” and inconclusive urine results, cardiac blood was tested specifically for the presence of carfentanil, which was ultimately positive at very low quantities (0.12 ng/mL). Additional testing of vitreous humor showed cocaine (40 ng/mL) and benzoylecgonine (510 ng/mL), but no evidence of carfentanil. Autopsy showed mild left ventricular hypertrophy. Ultimately, given the significant history and positive cardiac blood toxicology, cause of death was determined as carfentanil intoxication [36].

Case 7: Illicit drug contamination with synthetic opioids [34].

A 43-year-old male presented to the hospital after ingesting what he believed to be a “30-mg Percocet” tablet. His urine toxicology screening was positive for benzodiazepines and marijuana, but no evidence of opioids. He was treated for an accidental overdose but eventually discharged from the hospital 5 h later before being found deceased. Postmortem femoral blood analysis was positive for isotonitazene (0.71 ng/mL), brorphine (3.6 ng/mL), THC (6.7 ng/mL), and diphenhydramine (530 ng/mL). His certified cause of death was listed as mixed drug toxicity [34].

Case 8: Illicit drug contamination with synthetic opioids [37].

A 43-year-old male with a known history of opioid dependency presented to the emergency department (ED) with acute opioid overdose. He was prescribed buprenorphine as an opioid substitute but admitted to relapsing with heroin and crack cocaine approximately once per month. Before presenting at the ED, he smoked his normal amount of “heroin” before feeling excessively dizzy after only a few inhalations. Nearby witnesses saw him collapse and quickly administered 2 mg of intramuscular naloxone and he quickly regained consciousness with a Glasgow Coma Score (GCS) of 15/15. Vitals signs and electrocardiogram (ECG) in the ED were significant for hypertension but otherwise unremarkable. His blood work showed evidence of acute kidney injury and the presence of isotonitazene (0.18 ng/mL), cocaine, cocaine metabolites, buprenorphine, and buprenorphine metabolites. He was kept overnight for observation and intravenous (IV) fluids and ultimately released the following day when his kidney function had normalized [37].

Case 9: Ineffective dose of Narcan with synthetic opioids [33].

A 33-year-old female with a recent overdose 1 week prior was found deceased in her bathroom surrounded by drug paraphernalia. A naloxone dose was found in the bathroom and a single dose had been administered. Postmortem analysis of iliac blood was positive for carfentanil (145 ng/L), morphine (10.9 μg/L), THC (2.7 μg/L), and 11-nor-9-carboxy-delta-9-tetrahydrocannabinol (29.0 μg/L). Urine was positive for 11-nor-9-carboxy-delta-9-tetrahydrocannabinol, morphine, and codeine. No autopsy findings were available, but the cause of death was listed as mixed drug intoxication [33].

Case 10: Extended bioavailability of synthetic opioids leading to re-intoxication following naloxone administration [37].

A 41-year-old male with a history of crack cocaine and cannabis use was found unresponsive on the steps of his apartment. Of note, the patient had a history of intentional overdose with prescription medications in the setting of depression a few years prior. At the time of his death, he was prescribed sertraline to manage his depression. Upon arrival, emergency services noted significant respiratory depression and began cardiopulmonary resuscitation (CPR). They administered two doses of 400 μg naloxone intravenously after which he regained consciousness. Following administration of naloxone, his GCS was 14/15. Upon arrival at the hospital, his GCS slightly decreased to 13/15. Given his apparent respiratory difficulties, chest x-ray and polymerase chain reaction (PCR) testing were performed to rule out possible COVID-19 infection. During his hospital stay, the patient admitted to smoking a new “resin,” which he believed to be cannabis, but denied any history of IV drug or heroin drug use. Forty-six minutes following his previous naloxone dose, he again showed signs of respiratory distress and required an additional four doses of 200 μg IV naloxone for a total dose of 800 μg. His symptoms improved temporarily, but 2 h later, he showed signs of respiratory depression. Ultimately, he was started on a continuous infusion of IV naloxone at a rate of 480 μg/h for 12 h. Upon completing this infusion, he showed no additional signs of respiratory changes and was ultimately discharged 21 h after his initial presentation. His toxicology report at the time of admission was positive for cocaine, buprenorphine metabolites, and isotonitazene (0.81 ng/mL) [37].

Case 11: Prolonged bioavailability of synthetic opioids [33].

A 28-year-old male with a history of heroin use was found deceased in his jail bed. History suggested heroin use the previous night. Subsequent blood analysis from the iliac was positive for carfentanil (23.3 ng/L) and 11-nor-9-carboxy-delta-9-tetrahydrocannabinol (9.6 μg/L). Autopsy revealed pulmonary edema and cause of death was acute carfentanil intoxication [33]. Table 2 summarizes the cases spoken of in this section and additional cases seen in the literature.

Table 2 Clinical cases involving synthetic opioids
Full size table

Traditional toxicology screenings may not have the necessary sensitivity to detect these compounds at such low doses post-mortem, particularly when blood is drawn from the periphery instead of central tissues such as the brain, lung, or heart [33, 35, 36, 39]. Additional analysis and specific testing may be required when the history, clinical presentation, or other factors suggest opioid intoxication [35, 36]. In addition to high-sensitivity testing, laboratories need to work closely with law enforcement and public health officials to remain current on regional and temporal shifts in recreational drug use to ensure proper screening as new synthetic opioids continue to emerge in the local drug supply [34, 40].

Naloxone is an effective treatment against lethal doses of carfentanil in animal models. Yet there has been some evidence to suggest that a much higher dose of naloxone is required due to the relative potency and extended bioavailability of synthetic opioids [33, 37, 41,42,43]. Patients with suspected synthetic opioid intoxication should be closely monitored following administration of naloxone given the increased risk of re-intoxication due to the extended bioavailability outlasting the antagonist effects of naloxone [37].

Conclusions

New synthetic opioids, carfentanil, protonitazene, and isotonitazene, play a detrimental role in the opioid epidemic. The potency and efficacy of these synthetic opioids increase the overdose potential substantially and have raised fatalities. These consequences and outcomes are a dire matter, especially to unsuspecting users. The addition of these cheap and easily attainable fentanyl analogs has infiltrated the drug market. As seen in these case studies, a pattern of individuals with substance use disorder using drugs laced with carfentanil leading to overdose deaths has emerged. Additional challenges include the current treatment guidelines regarding OUD. The recommended dose of naloxone does not appear to be effective enough at reversing the effects of the synthetic opioids. As seen in the case studies, treatment attempts with naloxone were unsuccessful. Substantial evidence determines a need in treatment research to battle this evolving crisis. The appropriate dosage of naloxone and continued treatment guidelines must be updated to handle these stronger synthetic opioids. Advanced and expedited pharmaceutical research is of utmost need to identify effective alternative reversal remedies for overdosages and alternative pain-reducing formulas/medications [44,45,46].

As we move forward, it will take collaboration from medical professionals, policy makers, and law enforcement to battle the opioid crisis. From education of OUD treatment and appropriate guidelines to pharmaceutical advancements, various entities, agencies, and measures can all be simultaneously implemented to effectively treat OUD, reduce addiction, and prevent further substance use. Moreover, raising awareness of the dangers of the new synthetic opioids to those at risk and providing support may reduce the number of fatal overdoses.